Pasithea

Contributing Author

Recent Articles by Pasithea

Jul-21	Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026 KTTA GlobeNewswire
Jul-08	Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit KTTA GlobeNewswire
Jun-30	Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion KTTA GlobeNewswire
Jun-16	Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial KTTA -8.93% GlobeNewswire
Jun-15	Pasithea Therapeutics Announces Exhibit at Children's Tumor Foundation 2026 NF Conference KTTA -5.26% GlobeNewswire
Jun-02	Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS) KTTA -9.79% GlobeNewswire
May-04	Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer KTTA GlobeNewswire
Apr-20	Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) KTTA GlobeNewswire
Apr-01	Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity KTTA GlobeNewswire
Feb-17	Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference KTTA GlobeNewswire
Jan-13	Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines KTTA GlobeNewswire
Dec-02	Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock KTTA GlobeNewswire
Nov-28	Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock KTTA +38.68% GlobeNewswire
Nov-25	Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS KTTA +14.78% GlobeNewswire
Nov-24	Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data KTTA +45.33% GlobeNewswire
Nov-21	Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients KTTA -29.58% GlobeNewswire
Nov-20	Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study KTTA -12.78% GlobeNewswire
Nov-04	Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients KTTA -5.87% GlobeNewswire
Sep-16	Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients KTTA GlobeNewswire
Sep-08	Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients KTTA GlobeNewswire
Aug-29	Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference KTTA GlobeNewswire
Aug-28	Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference KTTA +11.76% GlobeNewswire
Jul-31	Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients KTTA GlobeNewswire
Jun-11	Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board KTTA GlobeNewswire
Jun-02	Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025 KTTA GlobeNewswire
May-20	Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases KTTA GlobeNewswire
May-14	Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site KTTA +11.07% GlobeNewswire
May-07	Pasithea Therapeutics Announces Closing of $5 Million Public Offering KTTA -25.66% KTTA -15.04% GlobeNewswire
May-06	Pasithea Therapeutics Announces Pricing of $5 Million Public Offering KTTA +7.04% GlobeNewswire
May-06	Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004 KTTA +7.04% GlobeNewswire

Pasithea

Recent Articles by Pasithea

Upgrade your Finviz experience